Hereditary Angioedema: The Dawn of a New Era of Hereditary Angioedema Management

This symposium took place on 19th June 2017, as part of the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Helsinki, Finland

Chairpersons: Marco Cicardi,1 Timothy Craig2
Speakers: Markus Magerl,3 Bruce Zuraw4

1. Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
2. Division of Pulmonary, Allergy and Critical Care, Penn State University, Pennsylvania, USA
3. Department of Dermatology and Allergy, Charité University, Berlin, Germany
4. Division of Rheumatology, Allergy and Immunology, UC San Diego, San Diego, California, USA

Disclosure: Prof Cicardi has received grant support and personal fees from Shire, and personal fees from CSL Behring, Dyax, BioCryst, ViroPharma, SOBI–Pharming, Alnylam, KalVista, and Pharming. Prof Craig has received grant support and personal fees from Shire, CSL Behring, Grifols, and Biocryst. Prof Magerl has received consultancy/honorarium fees from Shire, Viropharma, CSL Behring, and Sobi. Prof Zuraw has received personal fees from CSL Behring, grant support from the Department of Defence, and personal fees from Alnylam, Arrowhead, BioCryst, Nektar, and Shire.
Acknowledgements: Writing assistance was provided by Mia Cahill, ApotheCom, London, UK.
Support: The publication of this article was funded by CSL Behring. The views and opinions expressed are those of the authors and not necessarily CSL Behring.
Citation: EMJ. 2017;2[4]:36-42.

Meeting Summary

This symposium provided an overview of past, current, and future therapies and routes of administration for patients with hereditary angioedema (HAE). Prof Cicardi opened the symposium by welcoming attendees and introducing the main topics of the session. Prof Magerl then focussed on treatments that are currently used for acute and prophylactic management of patients with HAE and highlighted that there is an unmet medical need in terms of better prophylactic treatment options. Prof Craig summarised the clinical evidence gathered over the last decades and shared the key findings and insights that led to our current understanding of the disease and laid the foundations for current and future treatment approaches. Prof Zuraw presented the findings from the pivotal Phase III COMPACT trial that explored the efficacy and safety of a self-administered subcutaneous (SC) nanofiltered C1-esterase inhibitor concentrate (C1-INH[SC]) for the prevention of HAE attacks.

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Download (PDF, 113KB)

Comments are closed.